Synopen

Synopen was an early-stage biotechnology company focused on developing a novel platform to transiently modulate the blood-brain barrier (BBB). The company's technology aimed to identify and target specific molecular pathways that regulate the permeability of the BBB, allowing for the effective delivery of therapeutic agents to the central nervous system. By enabling drugs to bypass the restrictive barrier, Synopen sought to improve treatment outcomes for a wide range of neurological and psychiatric conditions, including neurodegenerative diseases and brain tumors. Although the company was active in the mid-2010s and produced significant intellectual property regarding BBB regulation, it appears to have ceased active operations or transitioned into a dormant state.